Key points are not available for this paper at this time.
Introduction HbA1c 8.6±1.1%; age 38±12 years; diabetes duration 22±12 years; 61% used carbohydrate counting). The iBolus DSS reduced mean HbA1c from 8.6% to 8.1% while the control intervention reduced HbA1c from 8.6% to 8.5%; a treatment effect in favor of the DSS of -0.40% (95% CI: -0.75 to -0.051; p=0.025). The proportion of participants with improvements in HbA1c of 0.5%, 1.0%, 1.5%, and 2.0% were almost doubled in the DSS arm compared to the control arm (52%, 19%, 12%, and 5% vs. 31%, 10%, 5%, and 0%, respectively). Differences in FGM outcomes were not statistically significant. There were no cases of severe hypoglycemia or diabetic ketoacidosis in either group. Conclusion: Our iBolus DSS significantly improves HbA1c in adults with suboptimal glucose control on MDI therapy. Disclosure A. Kobayati: None. A. El Fathi: None. N. Garfield: None. L. Legault: Advisory Panel; Abbott, Novo Nordisk. Speaker's Bureau; Novo Nordisk. Advisory Panel; Dexcom, Inc. J. Yale: Speaker's Bureau; Novo Nordisk Canada Inc., Abbott, Eli Lilly and Company. Advisory Panel; Novo Nordisk Canada Inc., Bayer Inc. Speaker's Bureau; Insulet Corporation. Advisory Panel; Eli Lilly and Company. Speaker's Bureau; Dexcom, Inc., Sanofi, Janssen Pharmaceuticals, Inc. Advisory Panel; Boehringer-Ingelheim, Mylan. Speaker's Bureau; Bayer Inc. Advisory Panel; Sanofi. Speaker's Bureau; Merck Bayer Inc., Novartis Canada, Novo Nordisk Canada Inc. M. Tsoukas: Speaker's Bureau; Novo Nordisk, Eli Lilly and Company, Boehringer-Ingelheim, Janssen Pharmaceuticals, Inc., AstraZeneca, Sanofi, Bausch Health, Abbott. A. Haidar: Consultant; Eli Lilly and Company. Other Relationship; Bigfoot Biomedical, Inc. Research Support; ADOCIA, Tandem Diabetes Care, Inc., Dexcom, Inc., Ypsomed AG. Funding CIHR
KOBAYATI et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: